First Author: N.Arruti UK
Co Author(s): R. Alieldin A. Hawrami H. Zambarakji S. Patra
Back to previous
To assess the efficacy and safety of fluocinolone acetonide intravitreal implant (Iluvien®) in patients with diabetic macular oedema (DMO).
Retrospective study of all the patients who received a fluocinolone acetonide intravitreal implant between the years 2014 and 2017 at Whipps Cross University Hospital (London).
41 subjects previously diagnosed with DMO received the Iluvien® implant between January 2014 and February 2017. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed at baseline, 2-4 weeks, 3 months, 1 year and 2 years.
All our patients were examined at baseline and at 2-4 weeks. The mean BCVA at baseline was 0.60 LogMAR (SD ± 0.25) and the mean CMT was 459 microns (SD ± 118.6). At 2-4 weeks, the mean BCVA remained unchanged and the mean CMT was 403 microns (SD ± 84 microns). At the 3 month visit 33 patients were examined. The mean BCVA improved to 0.55 LogMAR (SD ± 0.27) with a further reduction on the CMT (mean 392 microns, SD ± 100). One year after receiving the implant, 31 patients were examined. The BCVA continue to improve, with a mean of 0.54 LogMAR (SD ± 0.26) and a stable CMT (mean 394 microns, SD ± 116.6) was found. A total of 18 patients have been followed up for 2 years, showing a mean BCVA of 0.59 LogMAR (SD ± 0.3) and mean CMT of 421 microns (SD ± 82). Increase in intraocular pressure occurred in 24% patients, successfully controlled with topical treatment in all of them. During the 2 years period, 3 of our patients deceased.
Fluocinolone acetonide intravitreal implant improved BCVA in patients with DMO over the first year with a significant reduction of the CMT. At year 2, our data suggest a trend towards baseline in both BCVA and CMT. The number of subjects requiring glaucoma treatment after the implant remained low.